Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Human GenomicsOpen Access

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXiaodi YangZLZeyin LiangJLJi Li

Discussion

Loading...

Member takes

Overview

Observational analysis highlights survival differences based on tp53 mutations among MDS/AML patients, indicating its prognostic significance.

Key Points

  • Patients with tp53 mutations experienced significantly worse overall survival than those with tp53 snps or wild-type, with 2-year OS at 34.94%.
  • Key factors influencing prognosis included age, cytogenetic risk, and tp53 variant allele frequency > 40%, emphasizing the need for careful patient evaluation.
  • Transplantation notably improved survival compared to chemotherapy alone in patients with tp53 mutations, advocating for this intervention.
  • Further research with larger cohorts is essential to validate the findings and refine prognostic strategies based on tp53 alterations.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/68c238d2b210217d6477906chttps://doi.org/10.1186/s40246-025-00792-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of TP53 mutation status and variant allele frequency in myelodysplastic syndromes: A meta-analysis of prognosis and transplant outcomes2025
  2. 2Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  3. 3Functional classification of monoallelic TP53 mutations refines prognostic stratification in myelodysplastic neoplasms2025
  4. 4Decoding the molecular drivers of <i>TP53</i> ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights2025
  5. 5Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation2025